4//SEC Filing
Gordon David N. 4
Accession 0001209191-21-037484
CIK 0001557746other
Filed
Jun 1, 8:00 PM ET
Accepted
Jun 2, 9:49 PM ET
Size
15.8 KB
Accession
0001209191-21-037484
Insider Transaction Report
Form 4
Gordon David N.
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2021-06-01+87,500→ 195,992 total - Exercise/Conversion
Restricted Stock Units
2021-06-01−87,500→ 0 total→ Common Stock (87,500 underlying) - Sale
Common Stock
2021-06-01$23.57/sh−4,885$115,142→ 181,992 total - Sale
Common Stock
2021-06-01$22.71/sh−9,115$207,024→ 186,877 total - Sale
Common Stock
2021-06-02$21.50/sh−31,114$668,808→ 150,878 total - Sale
Common Stock
2021-06-02$22.26/sh−6,800$151,401→ 144,078 total
Footnotes (8)
- [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- [F2]These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021.
- [F3]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.24 to $23.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.33 to $23.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections.
- [F6]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.01 to $21.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.01 to $22.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The shares underlying these restricted stock units vested in two equal annual installments beginning on June 1, 2020.
Documents
Issuer
Aclaris Therapeutics, Inc.
CIK 0001557746
Entity typeother
Related Parties
1- filerCIK 0001751167
Filing Metadata
- Form type
- 4
- Filed
- Jun 1, 8:00 PM ET
- Accepted
- Jun 2, 9:49 PM ET
- Size
- 15.8 KB